Porida Biotechnology

Porida Biotechnology is a biopharmaceutical company focused on the development of next-generation immunotherapy drugs through its proprietary conditional activation platform. The company specializes in engineering "masked" biologics, such as cytokines and antibodies, that remain inactive in systemic circulation to prevent off-target toxicity. These therapeutic candidates are designed to be selectively activated by proteases within the tumor microenvironment, thereby concentrating the immune-stimulating effect where it is most needed. Porida's lead programs, including masked IL-2 and IL-12, aim to overcome the historical safety limitations of potent immune modulators. With operations in both the United States and China, the company is positioned to advance its pipeline through global clinical development.